Most Read Articles
Elvira Manzano, Yesterday
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Product Highlight - Crestor

26 Jun 2020
Crestor now can be prescribed for patients with severe renal impairment1
  • The usual dose range applies in patients with mild to moderate renal impairment.
  • For patients with severe renal impairment not on haemodialysis, dosing of Crestor should be started at 5 mg once daily and not exceed 10 mg.
Crestor improves cardiovascular outcomes in patients with chronic kidney disease.2
  • Among moderate CKD patients, rosuvastatin was associated with a 45% reduction in first cardiovascular events (myocardial infarction, stroke, hospital stay for unstable angina, arterial revascularisation, or confirmed cardiovascular death.

References:
1. Crestor Malaysia Package Insert, 2019
2. Ridker PM, et al. J Am Coll Cardiol. 2010:55(12):1266-1273



Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Yesterday
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, Yesterday
For individual with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.